Zilucoplan, now Zilbrysq, approved by FDA for AChR-positive gMG
The FDA has approved once-daily zilucoplan as Zilbrysq for adults with generalized MG who are positive for antibodies targeting AChR.| Myasthenia Gravis News
The FDA has approved once-daily zilucoplan as Zilbrysq for adults with generalized MG who are positive for antibodies targeting AChR.| Myasthenia Gravis News
Soliris (eculizumab) is an infusion therapy approved for treating adults with generalized myasthenia gravis.| Myasthenia Gravis News
Myasthenia gravis occurs when self-reactive antibodies mistakenly attack the body's immune system, causing muscle weakness and fatigue.| Myasthenia Gravis News
Category archive page for News.| Myasthenia Gravis News
Myasthenia gravis is a neuromuscular disease characterized by weakness and fatigue that can affect muscles involved in voluntary movements.| Myasthenia Gravis News
